Coadministration of a gastric acid‐reducing agent was tested as a covariate on the rate (Ka) and extent (F1) of venetoclax absorption in the stepwise model building procedure, but it did not reach statistical significance during the forward inclusion process.
← all excerpts
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
1
—
—